Donepezil palmitate or its pharmaceutically acceptable salt
By introducing the ether palmitate group into donepezil, the preparation of donepezil ether palmitate was solved, and the treatment effect of uniform release and low side effects in patients with dementia was achieved, and the treatment was improved. Compliance.
Patent Information
- Application Number
- CN202180055754.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-08-14
- Filing Date
- 2021-06-24
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-06-24
AI Technical Summary
The existing drug preparations for treating dementia in donepezil have high initial sudden release problems, which leads to a high risk of side effects and is difficult to release evenly over a long period of time, affecting the treatment effect and patient compliance.
The preparation of donepezil ether palmitate by introducing the ether palmitate group into donepezil, in the form of a sustained release pharmaceutical composition, reduces initial burst release and uniformly releases donepezil in the body, and optimizes drug treatment compliance.
It has achieved the maintenance of effective blood drug concentration of donepezil for a long time under the conditions of low risk of side effects, which has improved the drug treatment effect and compliance of dementia patients and reduced the frequency of drug administration.
Smart Images

Figure CN116018140B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a novel donepezil ether palmitate or a pharmaceutically acceptable salt thereof, and a sustained-release pharmaceutical composition comprising the same as a main component. Specifically, the present invention relates to donepezil ether palmitate or a pharmaceutically acceptable salt thereof, and an injectable composition comprising the same, which can maintain a constant blood concentration of the active ingredient donepezil when administered in vivo, and supply the active ingredient for a long time without the risk of side effects. Background Art
[0002] Dementia refers to a disease associated with complex cognitive impairment, which manifests as memory loss, intellectual decline, personality changes, abnormal behavior, etc. In other words, dementia is a degenerative cranial nerve disease caused by irreversible dysfunction in the neural network due to slow nerve cell death that causes degenerative diseases of the central nervous system, and ultimately leads to permanent loss of human function.
[0003] The mechanism of dementia has not been fully elucidated, but it is known that, in the brain of a dementia patient, choline acetyltransferase (hereinafter referred to as ChAT) that synthesizes acetylcholine (hereinafter referred to as ACh) is reduced by about 20% to 30% compared to a normal person, and the concentration of acetylcholine (a neurotransmitter) is reduced by about 16% to 30%. As a result of the above research, research has been conducted using an inhibitor that inhibits acetylcholinesterase (hereinafter referred to as AChE), which is an enzyme that hydrolyzes acetylcholine (a neurotransmitter), as an indirect treatment method.
[0004] Acetylcholinesterase is an enzyme that hydrolyzes acetylcholine (one of the neurotransmitters that mediate the activity of parasympathetic nerves in the body) into choline and acetate, and is formed in the endoplasmic reticulum membrane and moves to the cell membrane to exert its function. This enzyme is an important enzyme that is most distributed in cholinergic nerves and their surroundings (especially in neuromuscular junctions), and is found in plasma, liver, and other tissues.
[0005] Most of the therapeutic agents currently used for dementia are acetylcholinesterase inhibitors, which include Donepezil (trade name: Aricept), Tacrine (trade name: Cognex), Rivastigmine (trade name: Exelon), Galantamine (trade name: Reminyl), and the like.
[0006] The first generation of acetylcholinesterase inhibitors includes tacrine, which is the first drug approved as an anti-dementia therapeutic agent. However, tacrine needs to be administered four times a day due to its short duration of action and has the problem of causing liver toxicity.
[0007] The second generation acetylcholinesterase inhibitors include donepezil, which is a compound represented by the following chemical formula. Donepezil was approved for the treatment of dementia in the United States in 1996 and is known as a therapeutic agent for mild and moderate or more severe Alzheimer's disease, most of which are orally administered in the form of tablets.
[0008]
[0009] However, it is known that oral administration of donepezil tablets causes gastrointestinal side effects such as diarrhea, nausea, loss of appetite, muscle cramps, etc. in some patients. In addition, currently commercially available oral preparations of donepezil hydrochloride are usually administered once a day at a starting dose of 5 mg before bedtime and used for 4 to 6 weeks, and then the dose is increased to 10 mg once a day. However, treatment methods in this manner have the disadvantage of low drug compliance because the preparation must be orally administered every day, especially for patients with dementia.
[0010] In recent years, orally disintegrating tablets are commercially available for patients with dysphagia. In addition, when oral administration is difficult, transdermal administration of ointment preparations has been proposed (Japanese Publication (Ping) No. 11-315016). In addition, ointments, suppositories, etc. have been proposed to solve the situation where it is difficult to take drugs orally in a state where dementia symptoms have significantly progressed. However, these preparations also have the problem of having to continuously administer the active ingredient over a long period of time.
[0011] In order to maintain a stable drug concentration for a long period of time, while improving patient convenience and compliance by reducing the frequency of drug administration, there is a method for preparing a sustained-release injection. However, when a sustained-release injection is administered, it is difficult to ensure that the drug is continuously and uniformly released over a long period of time while maintaining its biological activity in the body.
[0012] In particular, since sustained-release injections have a high initial burst release, which may cause side effects including toxic reactions, it is desirable to eliminate or at least minimize the high initial burst release.
[0013] Therefore, there is a need to develop a formulation that can suppress the high initial burst release of donepezil and continuously release donepezil over a long period of time.
[0014] Therefore, the inventors of the present invention developed donepezil ether palmitate in which an ether palmitate group was introduced into donepezil to enable sustained and uniform release of donepezil in vivo while reducing the high initial burst release of donepezil, and completed the present invention. Summary of the invention
[0015] Technical issues
[0016] An object of the present invention is to provide donepezil palmitate or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same, which, when administered into the body, can improve the drug treatment compliance of dementia patients with a low risk of side effects.
[0017] Specifically, the present invention provides donepezil ether palmitate or a sustained-release pharmaceutical composition containing the same, which can reduce the initial burst release of donepezil to reduce the risk of side effects (such as drug toxicity) and allow donepezil to be released uniformly in the body over a long period of time to improve the drug treatment effect for dementia patients.
[0018] Technical Solution
[0019] The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:
[0020] [Chemical formula 1]
[0021]
[0022] In the above chemical formula,
[0023] R1 and R2 are each independently hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or aryl; and
[0024] R3 is C 12 -C 16 alkyl.
[0025] In addition, the present invention provides a sustained-release pharmaceutical composition for preventing or treating dementia, comprising the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof.
[0026] In addition, the present invention provides 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate or a pharmaceutically acceptable salt thereof represented by the following Chemical Formula 2:
[0027] [Chemical formula 2]
[0028]
[0029] In addition, the present invention relates to a sustained-release pharmaceutical composition for preventing or treating dementia, comprising the compound represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof.
[0030] The chemical name of the compound represented by Chemical Formula 2 is "2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate", and in the present invention, the compound in which an ether palmitate group is introduced into donepezil according to the present invention is referred to as donepezil ether palmitate (DEP).
[0031] The donepezil ether palmitate of the present invention can be prepared by reacting donepezil free base with 2-(tetradecyloxy)acetyl chloride.
[0032] 2-(Tetradecyloxy)acetyl chloride can be prepared by a process comprising the steps of: (i) mixing 1-tetradecanol, sodium chloroacetate, and potassium hydroxide to obtain sodium 2-(tetradecyloxy)acetate; (ii) reacting sodium 2-(tetradecyloxy)acetate with aqueous HCl to obtain 2-(tetradecyloxy)acetic acid; and (iii) reacting 2-(tetradecyloxy)acetic acid with oxalyl chloride.
[0033] The pharmaceutical composition of the present invention can be formulated as a preparation for parenteral administration (eg, intramuscular injection, intravenous injection, subcutaneous injection, intradermal injection or intravenous drip), preferably as a preparation for intramuscular injection.
[0034] The pharmaceutical composition of the present invention is preferably administered once every 2 to 20 weeks, more preferably once every 4 to 16 weeks.
[0035] Beneficial effects
[0036] The donepezil ether palmitate or its pharmaceutically acceptable salt and the sustained-release pharmaceutical composition containing the same as the main component of the present invention can have a low initial burst release of donepezil after administration into the body, thereby minimizing the risk of side effects including toxic reactions, and can maintain the effective concentration of donepezil in the blood for a long time to show a therapeutic effect (even in the case of a single administration), thereby improving the drug treatment compliance of dementia patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 Shown is the concentration of donepezil in the blood measured after administration of donepezil (D) to rats.
[0038] Figure 2 Shown are the concentrations of donepezil in the blood measured after administration of donepezil ether palmitate (DEP) to rats. DETAILED DESCRIPTION
[0039] definition
[0040] As used herein, "alkyl" is a hydrocarbon having primary, secondary, tertiary or quaternary carbon atoms, and includes saturated aliphatic groups that can be linear, branched or cyclic, or combinations thereof. For example, an alkyl group can have 1 to 20 carbon atoms (i.e., C1-C 20 alkyl), 1 to 10 carbon atoms (i.e. C1-C 10 alkyl) or 1 to 6 carbon atoms (i.e., C1-C6 alkyl). Examples of suitable alkyl groups may include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, isopropyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, isobutyl, -CH2CH(CH3)2), 2-butyl (s-Bu, sec-butyl, -CH(CH 3)CH2CH3), 2-methyl-2-propyl (t-Bu, tert-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH 2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(C H3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3) and octyl (-(CH2)7CH3).
[0041] "Alkoxy" refers to a group having an -O-alkyl moiety, wherein the alkyl group as defined above is attached to the parent compound via an oxygen atom. The alkyl portion of the alkoxy group may have, for example, 1 to 20 carbon atoms (i.e., C1-C 20Alkoxy), 1 to 12 carbon atoms (i.e. C1-C 12 Alkoxy), 1 to 10 carbon atoms (i.e. C1-C 10 The alkoxy group may be any of a plurality of carbon atoms (i.e., C1-C6 alkoxy) or a plurality of carbon atoms (i.e., C1-C6 alkoxy). Examples of suitable alkoxy groups may include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt) and tert-butoxy (-OC(CH3)3 or -O-tBu).
[0042] As used herein, the terms "halo" and "halogen" mean halogen and include chloro, fluoro, bromo and iodo.
[0043] "Haloalkyl" is an alkyl group in which at least one of the hydrogen atoms of the alkyl group as defined above is replaced by a halogen atom. The alkyl portion of the haloalkyl group may have, for example, 1 to 20 carbon atoms (i.e., C1-C 20 haloalkyl), 1 to 12 carbon atoms (i.e. C1-C 12 haloalkyl), 1 to 10 carbon atoms (i.e. C1-C 10 -C1-C6 haloalkyl) or 1 to 6 carbon atoms (i.e., C1-C6 haloalkyl). Examples of haloalkyl may include, but are not limited to, -CF3, -CHF2, -CFH2, and -CH2CF3.
[0044] "Aryl" includes monocyclic, bicyclic or polycyclic, substituted or unsubstituted, monovalent or divalent aromatic hydrocarbon groups, wherein each atom of the ring is carbon. Preferably, the aromatic ring is a 6 to 20 ring, a 6 to 14 ring, a 6 to 10 ring or more preferably a 6 ring. Aryl can be a polycyclic ring system with two or more cyclic rings (wherein two adjacent rings have two or more carbons), wherein at least one of these rings is aromatic and other cyclic rings can be, for example, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocycloalkyl. Aryl can include benzene, naphthalene, phenanthrene, anthracene, indene, indane, phenol, aniline etc.
[0045] The term "Cx-y" or "Cx-Cy" when used with a chemical moiety such as an alkyl, haloalkyl, or alkoxy group is intended to include groups containing from x to y carbons in the chain. If the group is at the end of the carbon chain, the C0 alkyl represents hydrogen, or if it is within the chain, the C0 alkyl represents a bond. For example, C1-C 20 Alkyl groups contain 1 to 20 carbon atoms in the chain.
[0046] Hereinafter, the present invention will be described in more detail by the following examples. However, these examples are provided only for illustrative purposes to facilitate understanding of the present invention, and the scope of the present invention is not limited by the following examples.
[0047] [Example 1]
[0048] Synthesis of 2-(Tetradecyloxy)acetyl chloride (EPS-Cl)
[0049]
[0050] 1) Preparation of 2-(tetradecyloxy) sodium acetate (EPS-Na)
[0051] 400 g of 1-tetradecanol was added to the reaction vessel and dissolved at 60° C., followed by 108.7 g of sodium chloroacetate and 108 mL of n-heptane. 78.5 g of potassium hydroxide was added to the reaction solution, and the mixture was heated to 85° C. and stirred for 3 hours. 980 mL of n-heptane and 2.2 L of ethanol were injected into the reaction solution, and the reaction solution was stirred at 60° C. for 1 hour, and cooled to room temperature, followed by filtration to obtain 263.3 g of sodium 2-(tetradecyloxy)acetate compound.
[0052] ( 1 H NMR (CD3OD, 400MHz) δ3.83 (s, 2H), 3.48 (t, J = 6.9 Hz, 2H), 1.65 ~ 1.57 (m, 2H), 1.37 ~ 1.29 (m, 22H), 0.90 (t, J = 6.9 Hz, 3H)).
[0053] 2) Preparation of 2-(tetradecyloxy)acetic acid (EPS-acid)
[0054] Into the reaction vessel, 263.3g of 2-(tetradecyloxy) sodium acetate prepared in 1) was added to 2.2L of ethyl acetate and stirred, then 1.45L of 2M HCl aqueous solution was injected and stirred at room temperature for 2 hours. The resulting product was subjected to layer separation to obtain an organic layer, which was then washed twice with 1.45L of purified water. The obtained organic layer was washed with 1.45L of saturated sodium chloride aqueous solution. After obtaining the organic layer, it was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was dissolved in 1.63L of n-hexane, and the mixture was then stirred at 0°C for 1 hour. The precipitated solid was filtered to obtain 110.6g of 2-(tetradecyloxy) acetic acid compound.
[0055] ( 1 H NMR (CDCl3, 400MHz) δ4.11 (s, 2H), 3.56 (t, J = 6.7Hz, 2H), 1.66 ~ 1.59 (m, 2H), 1.36 ~ 1.25 (m, 22H), 0.88 (t, J = 7.2Hz, 3H)).
[0056] 3) Preparation of 2-(tetradecyloxy)acetyl chloride (EPS-Cl)
[0057] 50.0 g of 2-(tetradecyloxy)acetic acid prepared in '2)' was added to the reaction vessel and dissolved by injecting 500 mL of dichloromethane and 0.5 mL of dimethylformamide. 16.5 mL of oxalyl chloride was injected into the reaction solution and stirred at room temperature for 3 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain 53.4 g of 2-(tetradecyloxy)acetyl chloride compound.
[0058] ( 1 H NMR (CDCl3, 400MHz) δ4.39 (s, 2H), 3.56 (t, J = 6.6 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.36 ~ 1.25 (m, 22H), 0.88 (t, J = 6.8 Hz, 3H)).
[0059] [Example 2]
[0060] Preparation of donepezil ether palmitate (DEP) [2-(tetradecyloxy)acetic acid 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl ester]
[0061]
[0062] 63.3 g of donepezil free base (purchased from Jinan Chenghui-Shuangda Chemical Co., Ltd) was added to the reaction vessel, and then 190 mL of tetrahydrofuran and 127 mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) were injected, dissolved, and cooled to -20° C. 183.5 mL of NaHMDS (1.0 M tetrahydrofuran solution) was injected into the reaction solution over 30 minutes, and the mixture was stirred at -20° C. for 1 hour. The reaction solution was injected into a solution in which 53.4 g of 2-(tetradecyloxy)acetyl chloride prepared in 'Example 1-3)' was dissolved in 380 mL of tetrahydrofuran and 253 mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) at -20°C over 40 minutes, and stirred at the same temperature for 1 hour.
[0063] 630mL of saturated aqueous ammonium chloride solution was injected into the reaction solution, filtered through diatomite, then washed with 630mL of ethyl acetate, and filtered. The resulting product was subjected to layer separation to obtain an organic layer, and the aqueous layer was stripped with 630mL of ethyl acetate. The combined organic layer was washed three times with 630mL of 5% sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 630mL of n-hexane was injected into the concentrated solution and stirred at 40°C, and the temperature was lowered back to room temperature and the slurry was stirred for 1 hour. The solution was filtered and the resulting filtrate was concentrated under reduced pressure. The concentrated solution was purified with a silica column and recrystallized with 630mL of n-heptane to obtain 33.1g of donepezil ether palmitate.
[0064] ( 1 H NMR(CDCl3,400MHz)δ7.32~7.21(m,5H),6.96(s,1H),6.59(s,1H),4.37(s, 2H),3.88(s,3H),3.87(s,3H),3.64(t,J=6.7Hz,2H),3.47(s,2H),3.25(s,2 H),2.87~2.84(m,2H),2.27(d,J=7.1Hz,2H),1.90(t,J=10.7Hz,2H),1.71~ 1.63(m,4H),1.55~1.44(m,1H),1.41~1.25(m,24H),0.88(t,J=6.8Hz,3H)).
[0065] [Example 3]
[0066] Synthesis of 2-(Dodecyloxy)acetyl chloride (EMS-Cl)
[0067]
[0068] 1) Preparation of 2-(dodecyloxy) sodium acetate (EMS-Na)
[0069] Into the reaction vessel, 96.0g of 1-dodecanol was added and dissolved at 60°C, and then 30.0g of sodium chloroacetate and 30mL of n-heptane were added. 22.8g of potassium hydroxide was added to the reaction solution, and the mixture was heated to 85°C and stirred for 2 hours. 270mL of n-heptane and 600mL of ethanol were injected into the reaction solution, stirred at 60°C for 20 minutes, and cooled to room temperature, followed by filtration to obtain 69.2g of 2-(dodecyloxy)acetic acid sodium compound.
[0070] ( 1H NMR (CD3OD, 400MHz) δ3.83 (s, 2H), 3.47 (t, J = 6.9 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.37 ~ 1.29 (m, 18H), 0.90 (t, J = 6.9 Hz, 3H)).
[0071] 2) Preparation of 2-(dodecyloxy)acetic acid (EMS-acid)
[0072] In the reaction vessel, 68.0g of 2- (dodecyloxy) sodium acetate prepared in '1)' above was added to 904mL of ethyl acetate and stirred, then 904mL of 2M HCl aqueous solution was injected and stirred at room temperature for 1 hour. The resulting product was separated into layers to obtain an organic layer, and washed twice with 904mL of purified water. The obtained organic layer was washed with 904mL of saturated sodium chloride aqueous solution. After obtaining the organic layer, it was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was dissolved in 300mL of n-hexane, and the mixture was then stirred at 0°C for 1 hour. The precipitated solid was filtered and washed with 60mL of cold n-hexane to obtain 36.2g of 2- (dodecyloxy) acetic acid compound.
[0073] ( 1 H NMR (CDCl3, 400MHz) δ4.11 (s, 2H), 3.56 (t, J = 6.7 Hz, 2H), 1.66 ~ 1.59 (m, 2H), 1.36 ~ 1.25 (m, 18H), 0.87 (t, J = 6.9 Hz, 3H)).
[0074] 3) Preparation of 2-(dodecyloxy)acetyl chloride (EMS-Cl)
[0075] 35.4 g of 2-(dodecyloxy)acetic acid prepared in '2)' was added to the reaction vessel and dissolved by injecting 354 mL of dichloromethane and 0.35 mL of dimethylformamide. 14.9 mL of oxalyl chloride was injected into the reaction solution and stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain 38.1 g of 2-(dodecyloxy)acetyl chloride compound.
[0076] ( 1 H NMR (CDCl3, 400MHz) δ4.39 (s, 2H), 3.57 (t, J = 6.6 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.36 ~ 1.26 (m, 18H), 0.88 (t, J = 6.8 Hz, 3H)).
[0077] [Example 4]
[0078] Preparation of donepezil ether myristate (DEM) [2-(dodecyloxy)acetic acid 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl ester]
[0079]
[0080] 50.0 g of donepezil free base (purchased from Jinan Chenghui-Shuangda Chemical Co., Ltd) was added to the reaction vessel, and then 150 mL of tetrahydrofuran and 100 mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) were injected, dissolved, and cooled to -20°C. 145 mL of NaHMDS (1.0 M tetrahydrofuran solution) was injected into the reaction solution over 30 minutes, and the mixture was stirred at -20°C for 1 hour. The reaction solution was injected into a solution in which 38.1 g of 2-(dodecyloxy)acetyl chloride prepared in the above 'Example 3-3)' was dissolved in 500 mL of tetrahydrofuran at -20°C over 30 minutes, and stirred at the same temperature for 30 minutes.
[0081] 500mL of saturated aqueous ammonium chloride solution was injected into the reaction solution, 100g of diatomaceous earth was added, and the mixture was stirred for 10 minutes. The reaction solution was filtered and washed with 500mL of ethyl acetate and filtered. The resulting product was subjected to layer separation to obtain an organic layer, and the water layer was stripped with 500mL of ethyl acetate. The combined organic layer was washed three times with 500mL of 5% sodium chloride aqueous solution. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 500mL of n-hexane was injected into the concentrated solution, and the slurry was stirred. The solution was filtered and the resulting filtrate was concentrated under reduced pressure. The concentrated solution was purified with a silica column and recrystallized with 750mL of n-heptane to obtain 26.7g of donepezil ether myristate.
[0082] ( 1H NMR(CDCl3,400MHz)δ7.32~7.21(m,5H),6.96(s,1H),6.59(s,1H),4.37(s, 2H),3.87(s,3H),3.87(s,3H),3.64(t,J=6.7Hz,2H),3.47(s,2H),3.25(s,2 H),2.87~2.84(m,2H),2.27(d,J=7.1Hz,2H),1.91(t,J=10.8Hz,2H),1.71~ 1.63(m,4H),1.55~1.44(m,1H),1.41~1.25(m,20H),0.88(t,J=6.8Hz,3H)).
[0083] [Example 5]
[0084] Synthesis of 2-(Tridecyloxy)acetyl chloride (EPDS-Cl)
[0085]
[0086] 1) Preparation of 2-(tridecyloxy) sodium acetate (EPDS-Na)
[0087] 100.0 g of 1-tridecanol was added to the reaction vessel and dissolved at 60 ° C, followed by 29.1 g of sodium chloroacetate and 30 mL of n-heptane. 21.0 g of potassium hydroxide was added to the reaction solution, and the mixture was heated to 85 ° C and stirred for 3 hours. 262 mL of n-heptane and 581 mL of ethanol were injected into the reaction solution, cooled to room temperature, and stirred for 16 hours. The solution was filtered to obtain 73.1 g of 2-(tridecanyloxy) sodium acetate compound.
[0088] ( 1 H NMR (CD3OD, 400MHz) δ3.83 (s, 2H), 3.47 (t, J = 6.9 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.37 ~ 1.29 (m, 20H), 0.90 (t, J = 6.8 Hz, 3H)).
[0089] 2) Preparation of 2-(tridecyloxy)acetic acid (EPDS-acid)
[0090] In the reaction vessel, 72.2g of 2-(tridecyloxy) sodium acetate prepared in '1)' above was added to 386mL of ethyl acetate and stirred, then 386mL of 2M HCl aqueous solution was injected and stirred at room temperature for 1 hour. 145mL of ethyl acetate was additionally added to the reaction solution, and the mixture was stirred at room temperature for 2 hours. The resulting product was subjected to layer separation to obtain an organic layer, and washed twice with 386mL of purified water. The obtained organic layer was washed with 386mL of 10% sodium chloride aqueous solution. After obtaining the organic layer, it was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated product was dissolved in 290mL of n-hexane at 40°C, and the mixture was stirred at room temperature for 1 hour and stirred for another 1 hour at 0 to 5°C. The precipitated solid was filtered and washed with 60mL of cold n-hexane to obtain 41.3g of 2-(tridecyloxy) acetic acid compound.
[0091] ( 1 H NMR (CDCl3, 400MHz) δ4.10 (s, 2H), 3.56 (t, J = 6.7Hz, 2H), 1.66 ~ 1.59 (m, 2H), 1.37 ~ 1.26 (m, 20H), 0.88 (t, J = 6.8Hz, 3H)).
[0092] 3) Preparation of 2-(tridecyloxy)acetyl chloride (EPDS-Cl)
[0093] 41.0 g of 2-(tridecyloxy)acetic acid prepared in '2)' was added to the reaction vessel and dissolved by injecting 410 mL of dichloromethane and 0.4 mL of dimethylformamide. 16.3 mL of oxalyl chloride was injected into the reaction solution and stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain 43.9 g of 2-(tridecyloxy)acetyl chloride compound.
[0094] ( 1 H NMR (CDCl3, 400MHz) δ4.39 (s, 2H), 3.57 (t, J = 6.6 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.36 ~ 1.26 (m, 20H), 0.88 (t, J = 6.8 Hz, 3H)).
[0095] [Example 6]
[0096] Preparation of donepezil ether pentadecanoate (DEPD) [2-(tridecyloxy)acetic acid 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl ester]
[0097]
[0098] 54.8 g of donepezil free base (purchased from Jinan Chenghui-Shuangda Chemical Co., Ltd) was added to the reaction vessel, and then 164 mL of tetrahydrofuran and 110 mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) were injected, dissolved, and cooled to -20°C. 159 mL of NaHMDS (1.0 M tetrahydrofuran solution) was injected into the reaction solution over 30 minutes, and the mixture was stirred at -20°C for 1 hour. The reaction solution was injected into a solution in which 43.9 g of 2-(tridecyloxy)acetyl chloride prepared in 'Example 5-3)' was dissolved in 548 mL of tetrahydrofuran at -20°C over 30 minutes, and stirred at the same temperature for 30 minutes.
[0099] 548mL of saturated aqueous ammonium chloride solution was injected into the reaction solution, 110g of diatomaceous earth was added, and the mixture was stirred for 10 minutes. The reaction solution was filtered and washed with 548mL of ethyl acetate and filtered. The resulting product was subjected to layer separation to obtain an organic layer, and the water layer was stripped with 548mL of ethyl acetate. The combined organic layer was washed three times with 548mL of 5% sodium chloride aqueous solution. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 548mL of n-hexane was injected into the concentrated solution, and the slurry was stirred. The solution was filtered and the resulting filtrate was concentrated under reduced pressure. The concentrated solution was purified with a silica column and recrystallized with 1.37L of n-heptane to obtain 27.2g of donepezil ether pentadecanoate.
[0100] ( 1 H NMR(CDCl3,400MHz)δ7.32~7.21(m,5H),6.96(s,1H),6.59(s,1H),4.37(s, 2H),3.87(s,3H),3.87(s,3H),3.64(t,J=6.7Hz,2H),3.47(s,2H),3.25(s,2 H),2.87~2.84(m,2H),2.27(d,J=7.1Hz,2H),1.91(t,J=10.8Hz,2H),1.71~ 1.63(m,4H),1.55~1.44(m,1H),1.43~1.25(m,22H),0.88(t,J=6.8Hz,3H)).
[0101] [Example 7]
[0102] Synthesis of 2-(pentadecyloxy)acetyl chloride (EHDS-Cl)
[0103]
[0104] 1) Preparation of 2-(pentadecyloxy) sodium acetate (EHDS-Na)
[0105] 200g of 1-pentadecanol was added to the reaction vessel and dissolved at 70°C to 80°C, and 51mL of n-heptane was injected. 51.0g of sodium chloroacetate and 36.8g of potassium hydroxide were added to the reaction solution. The reaction solution was heated to 90°C and stirred for 4 hours. 1L of ethanol and 450mL of n-heptane were injected into the reaction solution, and the mixture was stirred at 60°C for 1 hour. The reaction solution was cooled to room temperature again and stirred for 15 hours. The reaction solution was filtered and washed with a mixture of 150mL of ethanol and 75mL of n-heptane to obtain 130.7g of 2-(pentadecanyloxy) sodium acetate compound.
[0106] ( 1 H NMR (CD3OD, 400MHz) δ3.83 (s, 2H), 3.47 (t, J = 6.9 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.37 ~ 1.29 (m, 24H), 0.90 (t, J = 6.9 Hz, 3H)).
[0107] 2) Preparation of 2-(pentadecyloxy)acetic acid (EHDS-acid)
[0108] In the reaction vessel, 130.4g of 2-(pentadecyloxy) sodium acetate prepared in the above '1)' was added to 678mL of ethyl acetate and stirred, then 678mL of 2M HCl aqueous solution was injected and stirred at room temperature for 1 hour. 255mL of ethyl acetate was additionally added to the reaction solution, and the mixture was stirred at room temperature for 1 hour. The resulting product was subjected to layer separation to obtain an organic layer, and washed twice with 678mL of purified water. The obtained organic layer was washed with 678mL of saturated sodium chloride aqueous solution. Then, the obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was dissolved in 800mL of n-hexane at 40°C, and the mixture was then stirred at room temperature for 1 hour. The reaction solution was stirred for another 1 hour at 0°C. The precipitated solid was filtered and washed with 150mL of cold n-hexane to obtain 72.6 of 2-(pentadecyloxy) acetic acid compound.
[0109] ( 1 H NMR (CDCl3, 400MHz) δ4.11 (s, 2H), 3.56 (t, J = 6.7Hz, 2H), 1.69 ~ 1.56 (m, 2H), 1.37 ~ 1.25 (m, 24H), 0.88 (t, J = 6.8Hz, 3H)).
[0110] 3) Preparation of 2-(pentadecyloxy)acetyl chloride (EHDS-Cl)
[0111] 72.0 g of 2-(pentadecyloxy)acetic acid prepared in '2)' was added to the reaction vessel and dissolved by injecting 720 mL of dichloromethane and 0.7 mL of dimethylformamide. 25.9 mL of oxalyl chloride was injected into the reaction solution and stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain 76.6 g of 2-(dodecyloxy)acetyl chloride compound.
[0112] ( 1 H NMR (CDCl3, 400MHz) δ4.39 (s, 2H), 3.57 (t, J = 6.6 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.39 ~ 1.25 (m, 24H), 0.88 (t, J = 6.8 Hz, 3H)).
[0113] [Example 8]
[0114] Preparation of donepezil ether heptadecanoate (DEHD) [2-(pentadecyloxy)acetic acid 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl ester]
[0115]
[0116] 86.7 g of donepezil free base (purchased from Jinan Chenghui-Shuangda Chemical Co., Ltd) was added to the reaction vessel, and then 260 mL of tetrahydrofuran and 173 mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) were injected, dissolved, and cooled to -20°C. 251 mL of NaHMDS (1.0 M tetrahydrofuran solution) was injected into the reaction solution over 30 minutes, and the mixture was stirred at -20°C for 1 hour and heated to room temperature. The reaction solution was injected into a solution in which 76.6 g of 2-(pentadecyloxy)acetyl chloride prepared in the above 'Example 7-3)' was dissolved in 870 mL of tetrahydrofuran over 30 minutes at -20°C, and stirred at the same temperature for 30 minutes.
[0117] 867 mL of saturated aqueous ammonium chloride solution was injected into the reaction solution, filtered through diatomaceous earth, then washed with 867 mL of ethyl acetate, and filtered. The resulting product was subjected to layer separation to obtain an organic layer, and the aqueous layer was back-extracted with 867 mL of ethyl acetate. The combined organic layer was washed three times with 867 mL of 5% aqueous sodium chloride solution. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 867 mL of n-hexane was injected into the concentrated solution and stirred at 40° C., and the temperature was lowered back to room temperature and the slurry was stirred for 1 hour. The solution was filtered and the resulting filtrate was concentrated under reduced pressure. The concentrated solution was purified with a silica column and recrystallized with 2.6 L of n-heptane to obtain 55.2 g of donepezil ether heptadecanoate.
[0118] ( 1 H NMR(CDCl3,400MHz)δ7.32~7.21(m,5H),6.96(s,1H),6.59(s,1H),4.37(s, 2H),3.87(s,3H),3.87(s,3H),3.64(t,J=6.7Hz,2H),3.47(s,2H),3.25(s,2 H),2.87~2.84(m,2H),2.27(d,J=7.1Hz,2H),1.91(t,J=10.8Hz,2H),1.71~ 1.63(m,4H),1.53~1.45(m,1H),1.41~1.25(m,26H),0.88(t,J=6.8Hz,3H)).
[0119] [Example 9]
[0120] Synthesis of 2-(Hexadecyloxy)acetyl chloride (ESS-Cl)
[0121]
[0122] 1) Preparation of 2-(hexadecyloxy) sodium acetate (ESS-Na)
[0123] 104.1g of 1-hexadecanol was added to the reaction vessel and dissolved at 60°C, and 25.0g of sodium chloroacetate was added. The reaction solution was stirred for 10 minutes, and 25mL of n-heptane and 19.0g of potassium hydroxide were added. The reaction solution was heated to 80°C to 90°C and stirred for 3 hours. 333mL of ethanol and 167mL of n-heptane were injected into the reaction solution, and the mixture was stirred at 60°C for 20 minutes. The reaction solution was cooled to room temperature, filtered, and washed with a mixture of 167mL of ethanol and 37mL of n-heptane to obtain 70.9g of 2-(hexadecyloxy) sodium acetate compound.
[0124] (1 H NMR (CD3OD, 400MHz) δ3.83 (s, 2H), 3.47 (t, J = 6.8 Hz, 2H), 1.64 ~ 1.57 (m, 2H), 1.37 ~ 1.29 (m, 26H), 0.90 (t, J = 6.8 Hz, 3H)).
[0125] 2) Preparation of 2-(hexadecyloxy)acetic acid (ESS-acid)
[0126] In the reaction vessel, 70.0g of 2-(hexadecyloxy) sodium acetate prepared in the above '1)' was added to 1.4L of ethyl acetate and stirred, then 931mL of 2M HCl aqueous solution was injected and stirred at room temperature for 1 hour. The resulting product was subjected to layer separation to obtain an organic layer, and washed twice with 931mL of purified water. The obtained organic layer was washed with 931mL of saturated sodium chloride aqueous solution. Then, the obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was dissolved in 900mL of n-hexane at 40°C, and the mixture was then stirred at room temperature for 1 hour. The reaction solution was stirred for another 1 hour at 0°C. The precipitated solid was filtered and washed with 210mL of cold n-hexane to obtain 44.7g of 2-(hexadecyloxy) acetic acid compound.
[0127] ( 1 H NMR (CDCl3, 400MHz) δ4.10 (s, 2H), 3.57 (t, J = 6.7Hz, 2H), 1.66 ~ 1.59 (m, 2H), 1.37 ~ 1.26 (m, 26H), 0.88 (t, J = 6.8Hz, 3H)).
[0128] 3) Preparation of 2-(hexadecyloxy)acetyl chloride (ESS-Cl)
[0129] 44.3 g of 2-(hexadecyloxy)acetic acid prepared in '2)' was added to the reaction vessel and dissolved by injecting 880 mL of dichloromethane and 0.5 mL of dimethylformamide. 15.2 mL of oxalyl chloride was injected into the reaction solution and stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain 47.0 g of 2-(hexadecyloxy)acetyl chloride compound.
[0130] ( 1 H NMR (CDCl3, 400MHz) δ4.39 (s, 2H), 3.56 (t, J = 6.6Hz, 2H), 1.64 ~ 1.57z (m, 2H), 1.36 ~ 1.25 (m, 26H), 0.88 (t, J = 6.8Hz, 3H)).
[0131] [Example 10]
[0132] Preparation of donepezil ether stearate (DES) [2-(hexadecyloxy)acetic acid 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl ester]
[0133]
[0134] 50.9 g of donepezil free base (purchased from Jinan Chenghui-Shuangda Chemical Co., Ltd) was added to the reaction vessel, and then 152 mL of tetrahydrofuran and 102 mL of DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone) were injected, dissolved, and cooled to -20°C. 147 mL of NaHMDS (1.0 M tetrahydrofuran solution) was injected into the reaction solution over 30 minutes, and the mixture was stirred at -20°C for 1 hour and heated to room temperature. The reaction solution was injected into a solution in which 47.0 g of 2-(hexadecyloxy)acetyl chloride prepared in the above 'Example 9-3)' was dissolved in 508 mL of tetrahydrofuran at -20°C over 30 minutes, and stirred at the same temperature for 30 minutes.
[0135] Into the reaction solution, 509mL of saturated aqueous ammonium chloride solution was injected, filtered through diatomite, then washed with 500mL of ethyl acetate, and filtered. The resulting product was subjected to layer separation to obtain an organic layer, and the water layer was stripped with 500mL of ethyl acetate. The combined organic layer was washed three times with 509mL of 5% sodium chloride aqueous solution. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Into the concentrated solution, 509mL of n-hexane was injected and stirred at 40°C, and the temperature was lowered back to room temperature and the slurry was stirred for 1 hour. The solution was filtered and the resulting filtrate was concentrated under reduced pressure. The concentrated solution was purified with a silica column and recrystallized with 1.5L of n-heptane to obtain 28.7g of donepezil ether stearate.
[0136] ( 1H NMR(CDCl3,400MHz)δ7.32~7.21(m,5H),6.96(s,1H),6.59(s,1H),4.38(s, 2H),3.87(s,3H),3.87(s,3H),3.64(t,J=6.7Hz,2H),3.47(s,2H),3.25(s,2 H),2.87~2.84(m,2H),2.27(d,J=7.1Hz,2H),1.91(t,J=10.9Hz,2H),1.71~ 1.63(m,4H),1.52~1.45(m,1H),1.41~1.25(m,28H),0.88(t,J=6.7Hz,3H)).
[0137] [Example 11]
[0138] Preparation of donepezil compositions
[0139] Solution phase compositions were prepared using donepezil (D), Example 2 (DEP), Example 4 (DEM), Example 6 (DEPD), Example 8 (DEHD), and Example 10 (DES), each having a structure in Table 1 below.
[0140] [Table 1]
[0141]
[0142]
[0143] The main ingredients in Table 1 above, castor oil and benzyl benzoate were mixed according to the components and amounts in Table 2 below, and stirred at room temperature for 0.5 to 3 hours to prepare a solution phase composition.
[0144] [Table 2]
[0145]
[0146]
[0147] * denotes donepezil and corresponds to an equivalent dose
[0148] [Experimental Example 1]
[0149] Pharmacokinetic evaluation
[0150] Four male SD rats with an average body weight of 300 g were intramuscularly injected with 4 mg / kg of donepezil in the donepezil (D) formulation and 40 mg / kg of donepezil in each of the DEP, DEM, DEPD, DEHD and DES formulations, and the concentration of donepezil in the plasma samples of the SD rats was analyzed by LC-MS / MS.
[0151] As a result of the analysis, among the DEP, DEM, DEPD, DEHD and DES preparations, the release pattern when DEP was administered was the most preferred for the sustained-release composition, and the results for donepezil and DEP are shown in the following Tables 3 and Figure 1 and 2 middle.
[0152] [Table 3]
[0153] D DEP Cmax(ng / mL) 27.5 7.9 <![CDATA[AUC 最后 (ng / mL)]]> 367.6 6290.0
[0154] As shown in Table 3 and Figure 1 As shown, it was confirmed that when the donepezil (D) composition was administered, the drug was rapidly released immediately after administration, and the Cmax was as high as 27.5ngh / mL, indicating a high possibility of causing side effects or toxicity. In addition, the release of the drug was terminated within 3 days, confirming that the donepezil composition was not suitable as a sustained-release composition.
[0155] On the other hand, as shown in Table 3 and Figure 2 As shown, it was confirmed that when the composition of Example 2 (DEP) was administered, even if donepezil was administered in an amount about 10 times as much, Cmax was as low as 7.9 ngh / mL, while there was no rapid release of the drug after administration, and the difference between Cmax and the maintenance concentration was small. In addition, unlike the case where the donepezil (D) composition was administered, it was confirmed that the DEP composition maintained an effective blood drug concentration for a period of 8 weeks or longer even in the case of a single administration.
[0156] Therefore, it can be understood that donepezil ether palmitate (DEP) exhibits a better release pattern than donepezil. It can be confirmed that when DEP is administered into the body, sustained release can be maintained for a long period of time without rapid release of the drug after administration, thereby having excellent characteristics such as minimizing the risk of side effects including toxic reactions, while maintaining effective therapeutic drug concentrations for a long time even in the case of a single administration.
Claims
1. A compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof: [Chemical formula 1] In the above chemical formula, R1 and R2 are each independently hydrogen; and R3 is C 12 -C 16 alkyl.
2. 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate or a pharmaceutically acceptable salt thereof represented by the following Chemical Formula 2: [Chemical formula 2] 3. A sustained-release pharmaceutical composition for preventing or treating dementia, the sustained-release pharmaceutical composition comprising a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof: [Chemical formula 1] In the above chemical formula, R1 and R2 are each independently hydrogen; and R3 is C 12 -C 16 alkyl.
4. A sustained-release pharmaceutical composition for preventing or treating dementia, the sustained-release pharmaceutical composition comprising a compound represented by the following Chemical Formula 2 or a pharmaceutically acceptable salt thereof: [Chemical formula 2] 5. The sustained-release pharmaceutical composition according to claim 3 or 4, wherein the composition is for administration by injection once every 2 to 20 weeks.
6. The sustained-release pharmaceutical composition according to claim 3 or 4, wherein the composition is for intramuscular injection.
7. A process for preparing 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate, the process comprising reacting donepezil free base with 2-(tetradecyloxy)acetyl chloride.
8. A method for preparing 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-1H-inden-3-yl 2-(tetradecyloxy)acetate according to claim 7, wherein the 2-(tetradecyloxy)acetyl chloride is prepared by a method comprising the following steps: (i) mixing 1-tetradecanol, sodium chloroacetate and potassium hydroxide to obtain sodium 2-(tetradecyloxy)acetate; (ii) reacting the sodium 2-(tetradecyloxy)acetate with an aqueous HCl solution to obtain 2-(tetradecyloxy)acetic acid; and (iii) reacting the 2-(tetradecyloxy)acetic acid with oxalyl chloride.
